AC Immune (NASDAQ:ACIU) Upgraded to Buy at StockNews.com

StockNews.com upgraded shares of AC Immune (NASDAQ:ACIU) from a hold rating to a buy rating in a report published on Monday.

Other analysts also recently issued reports about the stock. BTIG Research started coverage on shares of AC Immune in a report on Friday, May 31st. They issued a buy rating and a $8.00 price target on the stock. HC Wainwright restated a buy rating and issued a $16.00 target price on shares of AC Immune in a report on Wednesday, September 18th.

AC Immune Stock Performance

Shares of NASDAQ ACIU opened at $3.70 on Monday. The company has a market cap of $365.93 million, a P/E ratio of -5.36 and a beta of 1.24. The firm’s fifty day moving average is $3.43 and its two-hundred day moving average is $3.39. AC Immune has a 52-week low of $2.20 and a 52-week high of $5.14.

AC Immune (NASDAQ:ACIU) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.67). The business had revenue of $0.76 million for the quarter, compared to the consensus estimate of $91.60 million. As a group, analysts forecast that AC Immune will post -0.89 EPS for the current fiscal year.

Institutional Trading of AC Immune

A number of large investors have recently made changes to their positions in the business. Redmile Group LLC increased its holdings in shares of AC Immune by 0.4% in the 1st quarter. Redmile Group LLC now owns 2,007,031 shares of the company’s stock worth $5,941,000 after buying an additional 7,031 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of AC Immune by 315.6% during the 1st quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock worth $33,000 after purchasing an additional 8,423 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in shares of AC Immune by 96.5% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 19,008 shares of the company’s stock worth $56,000 after purchasing an additional 9,334 shares during the period. Silverberg Bernstein Capital Management LLC purchased a new position in shares of AC Immune during the 2nd quarter worth about $40,000. Finally, Lazard Asset Management LLC purchased a new position in shares of AC Immune during the 1st quarter worth about $30,000. 51.36% of the stock is currently owned by institutional investors.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.